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Abstract. Background: Because phenothiazines inhibit efflux
pumps of bacteria, forty new phenothiazine derivatives were
tested for their inhibition of the efflux pump systems of Gram-
positive and Gram-negative pathogenic bacteria. Materials
and Methods: Detection of efflux pump activity was conducted
by a previously described automated fluorimetric method.
Results: Although many of the compounds significantly
inhibited efflux by distinct bacteria, four compounds had
exceptional activity against the efflux pump systems of the
pathogenic wild type bacteria Escherichia coli, Salmonella
Enteritidis, Enterococcus faecalis and Staphylococcus aureus.
These four compounds were then evaluated for ability to
reduce or reverse resistance of multi-drug resistant members
of Escherichia coli, Salmonella and Staphylococcus aureus
whose MDR phenotypes are mediated by specific over-
expressed efflux pumps. One of the compounds, 2173,
significantly reduced resistance of MDR Staphylococcus aureus.
Conclusion: These results suggest possible use of compound
2173 for therapy of infections caused by this organism.
Multi-drug resistant (MDR) bacterial clinical isolates owe their
MDR phenotypes to the over-expression of efflux pumps (1).
The intrinsic efflux pump system of Gram-negative (2-5) and
Gram-positive (6, 7) bacteria, which contribute to the intrinsic
resistance of these organisms, when over-expressed renders the
organism even more resistant to representatives of two or more
distinct antibiotic classes. How resistance develops in a patient
has been suggested to result from prolonged exposure to
increasing concentrations of a single antibiotic, which at first
promotes increases in the activity of genes that code for
regulators and transporters of a given bacterium (2, 3, 8). When
this is followed by exposure to a constant concentration of the
same antibiotic, this results in the gradual reduction of the
activity of the gene that codes for the transporter to levels
expressed by the non-antibiotic exposed control (wild-type),
with concomitant development of resistance to many antibiotics
(3). Whereas the increased resistance to the antibiotic following
serial exposure to increasing concentrations of a given
antibiotic is reversible, that which results from serial exposure
to a single concentration is not, suggesting the presence of
mutated targets (3). These results suggest that while a patient is
treated for prolonged periods with a single antibiotic, the
response of the bacterium evolves initially from protection
from the antibiotic by substantially increasing its capacity to
extrude the antibiotic, and, when the dose of the antibiotic is
maintained for long periods of time, the bacterium makes a
“decision” to mutate many antibiotic targets, rendering the
bacterium a truly MDR pathogen. This MDR pathogen pays a
survival cost since it cannot compete successfully with its wild-
type counterpart when co-cultured (3).
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The aforementioned results also suggest that evaluation of
a clinical isolate for its antibiotic susceptibility profile will
render results that reflect the point of evolution of resistance;
therefore, initially, over-expression of efflux pumps is readily
demonstrable, and with time, their activity is reduced when
mutations begin to appear and accumulate. Evaluation of
efflux pumps of MDR clinical isolates and their response to
agents that are being studied for potential efflux pump
inhibitory (EPI) capacities may not yield information that is
completely related to the efflux pump system. To this extent,
MDR clinical isolates that are shown to over-express an
efflux pump rarely assume an antibiotic response
characteristic of its wild-type counterpart when cultured in
the presence of an EPI. 
Given these apparent facts, we have chosen to use
reference strains representative of the four most frequent
bacterial pathogens for the evaluation of a series of
phenothiazine derivatives for inhibitory activity against their
efflux pump systems. Because the members of this series of
phenothiazines differ from each other by slight modification
of structure, it would be possible to perform quantitative
structure-activity relationships (QSARs) that would make it
possible to identify the component(s) of the phenothiazine
structure responsible for its EPI activity. Because the method
and system used for the evaluation of EPI activity is one that
provides a real-time assessment of EPI activity under
physiological conditions that lend themselves to manipulation
(9-14), the in vitro activity of the EPI may provide further
insight into the interaction between the EPI and the intrinsic
efflux pump of the organism.
Materials and Methods
Materials. Mueller-Hinton (MH) powder was purchased from
Sigma (Madrid, Spain) and used for the preparation of agar and
broth. Ethidium bromide (EB) and the EPI thioridazine (TZ) were
purchased from Sigma. Forty compounds evaluated for activity
against efflux pump systems of bacteria were derived from a
parental phenothiazine and the derivatives were made by chemical
manipulation. The phenothiazine derivatives were dissolved in
dimethyl sulfoxide (DMSO). The preparation of the particular
phenothiazine derivatives identified by code in this study will be
reported elsewhere pending protection of intellectual property
rights. 
Bacteria employed. Wild-type Escherichia coli K-12 AG100 strain
(argE3 thi-1 rpsL xyl mtl delta (gal-uvrB) supE44) (14) was kindly
provided by Hiroshi Nikaido, Department of Molecular and Cell
Biology and Chemistry, University of California, Berkely, CA, USA;
K-12 AG100TET and K-12 AG100ATET strains were derived from
their parental strains K-12 AG100 and K-12 AG100A (resistance
insertion marker, ΔacrAB::Tn903 Kanr) (15, 16) and induced to high
level resistance to tetracycline (Minimum inhibitory concentration
(MIC) 12 mg/L) by gradual exposure to the antibiotic (2). K-12
AG100TET and K-12 AG100ATET over-expressed AcrAB and AcrEF
efflux pumps, respectively (8). Wild-type ATCC 29212 Enterococcus
faecalis (7); wild-type ATCC 25923 Staphylococcus aureus (6) and
the progeny of methicillin-resistant Staphylococcus aureus (MRSA)
COLOXA strain induced to extremely high level resistance to
oxacillin by gradual exposure to the antibiotic (6) and over expressed
the NorA efflux pump (6, 17); Staphylococcus aureus HPV-107
strain has the QAC efflux pump (18); NCTC Salmonella Enteritidis
(19); Salmonella Enteritidis 104CIP (20) and Salmonella Enteritidis
5408CIP that were derived from parents gradually exposed to
ciprofloxacin achieving a high level of resistance to the antibiotic,
part of which was due to the over-expression of the AcrAB efflux
pump (19). 
Methods. Bacteria were cultured on MH agar and incubated
overnight; a single colony was transferred to MH broth incubated at
37˚C for 16 h and the MIC of all compounds against the bacteria
employed in this study were determined by micro-broth dilution as
per CLSI guidelines (21). The MIC of compounds to be evaluated
for effects on the efflux pump system is critical for it provides the
amount of compound which yields 50% the MIC, a relative
concentration which is known to have little or no effect on the
viability and replication of the bacterium (8). 
Detection of efflux pump activity in Escherichia coli AG100. This
was conducted by a semi-automated fluorimetric method previously
described (9, 10). Briefly, the method follows the real-time
accumulation of EB by the bacterial population with the aid of the
Rotor-Gene 3000™ thermocycler (Corbett Research, Sydney,
Australia) programmed for 30-40 cycles of 1 min each for a duration
of 25 min at a constant temperature of 37˚C. Bacteria are first grown
in MH broth until they reach an optical density (OD) of 0.6 at 600
nm. The cells are then centrifuged, washed twice with phosphate-
buffered saline (PBS) at pH 7.4, and the OD adjusted to 0.6 with
PBS (pH 7.4) containing 0.4% glucose, and aliquots of 0.045 mL
transferred to microtubes of 0.2 mL volume. Immediately, aliquots
of 0.045 mL of saline pH 7.4 containing EB and glucose to yield
final concentrations of 1 mg/L and 0.4%, respectively, with and
without varying concentrations of each compound to yield ½ of their
MIC value, were added. The concentration of DMSO in the assay
was not higher than 10%. The instrument was started and real-time
accumulation of EB (amount of relative fluorescence emitted)
followed up to 25 minutes, using excitation and emission
wavelengths of 535 nm and 586 nm, respectively. The difference
between the amount of fluorescence of compounds containing tubes
and control (no compound) at the end of 25 min provided an
estimation of the effect of the compound on accumulation of EB.
Previous studies amply demonstrated that the increased accumulation
of EB promoted by a compound over that of the control is a measure
of the effect of the compound on the efflux pump system of the
bacterium (9-12). Arbitrarily, agents that promote accumulation of
EB by at least two-fold over that taking place in the control at the
end of 25 min of assay are considered to be significantly active and
hence and used for further investigations.
Whether the degree of accumulation of EB noted is due to a direct
inhibition of the efflux or due indirectly to the effects on energy
sources, etc., cannot be determined from this method alone.
However, if the agent is to inhibit efflux (i.e. promote accumulation)
then it should be able to render the bacterium more susceptible to
antibiotics to which it was initially resistant due to its over-expressed
efflux pump system. In order to determine whether an agent that
significantly promotes accumulation renders the bacterium more
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susceptible to given antibiotics, the effect of the agent on the MIC
of a given antibiotic was determined as follows: firstly, an MIC of a
given antibiotic is determined and then the selected agent at a
concentration of equal to or less than ½ its MIC, is added in
combination with decreasing concentrations of the antibiotic that
range from its MIC to zero. For an agent to be considered an
inhibitor of efflux, it must reduce the MIC of the antibiotic by at
least two-fold (22). The use of an agent that is known to reduce the
MIC of a bacterial species that over-expresses its efflux pumps
served as a positive control. To this end, the phenothiazine TZ, a
proven inhibitor of efflux pumps of Escherichia coli (9-11, 14),
Enterobacter aerogenes (13), Salmonella Enteritidis (14),
Staphylococcus aureus (6, 18) and Enterococcus faecalis (7, 23, 24),
served as the positive control. The structures of thioridazine and
other phenothiazines from which it was derived, and which also have
EPI activity, are presented in Figure 1.
Determination of the ability of compounds that presented with
EPI-like activity to reduce the MIC of antibiotics whose resistance
was mediated by over-expression of efflux pumps was conducted as
follows (2, 4, 18): The MIC for the selected compounds was first
established for each of the pathogenic bacteria. Concentrations of
each compound at ¼ and ½ its MIC were then added to cultures of
the bacteria that contained increasing amounts of the antibiotic to
which they were initially resistant. At the end of 18 h, the cultures
were visually examined and cultures which had no visible turbidity
indicated the MIC of the antibiotic. 
Results
Graphical presentation of the effects of forty compounds
derived from a parental phenothiazine at a concentration
equivalent to ½ their MIC against four pathogenic bacteria on
the accumulation of EB by these bacteria is beyond the limits
of any journal. Consequently, Figure 2 serves to illustrate the
type of data generated by the method employed in this study.
The example is given for the Staphylococcus aureus ATCC
strain. From this data, three conclusions may be made: i. The
control bacterium does not appreciably accumulate EB during
the period of 25 min of the assay in PBS (pH 7.4) containing
0.4% glucose and 1 mg/L of EB as previously demonstrated
(4, 9-11); ii. The final concentration of DMSO of 10% does
not cause a change in the rate of accumulation of EB; iii.
Whereas compounds 1930 and 2115 marginally increased
accumulation of EB, compound 2173 promoted a five-fold
increase of accumulation. The data presented is for one of
each set of duplicates of the assay and the variation between
duplicates was not more than 5%. 
The effect of each compound on the accumulation of EB by
the pathogenic bacteria employed in this study may be
calculated by obtaining the difference between the average
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Figure 1. Structures of Pheothiazines: A. Methylene Blue; B. promethazine; C. chlorpromazine and D. thioridazine.
accumulation in the presence of the compound at ½ its MIC and
that of the average control. These differences are summarized
by Table I; compounds that inhibit accumulation of EB are
highlighted in the Table I. Briefly, it may be noted that although
many compounds inhibited accumulation of EB, with the
exception of 2158, no other compound had significant activity
on the accumulation of EB by each of the bacterium employed
in this assay. With respect to Escherichia coli, compounds 2158
and 2173 significantly increased accumulation of EB. With
respect to Salmonella Enteritidis, only compound 2158 had
activity. With respect to Enterococcus faecalis compounds 2158,
2167 and 2166 promoted significant accumulation; with respect
to Staphylococcus aureus, compounds 2173, 2166, 2158, 2167,
and 2164 had major effects on accumulation, and a number of
compounds had moderate effects considered to be significant
(example-2178, 2174, 2115, 1821, etc.). The data of Table I
suggest that Staphylococcus aureus, a representative of the
Gram-positive group, is very sensitive to many of the
phenothiazine derivatives, whereas Enterococcus faecalis,
another representative of the Gram-positive group, is far less
sensitive. 
In order that an agent is considered to be a true inhibitor
of an efflux pump it must be able to reduce the resistance of
the bacterium to a given antibiotic to which it was initially
resistant due to its over-expressed efflux pump system. The
most active agents of Table I against the efflux pump system
of wild-type strains of Escherichia coli, Staphylococcus
aureus and Salmonella Enteritidis were selected and evaluated
for their ability to reduce resistance of bacteria that over-
express a specific efflux pump (2, 5, 25). For this purpose we
selected Escherichia coli AG100TET that over-expresses the
AcrAB efflux pump by 16 times that of its tetracycline
sensitive parent and thus has high level resistance to
in vivo 25: 719-724 (2011)
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Figure 2. The effects of phenothiazine derivatives on the accumulation of
ethidium bromide by Staphylococcus aureus ATCC 25923. Accumulation
of EB by Staphylococcus aureus ATCC 25923 strain was incubated at
37˚C for 25 minutes in PBS (pH 5) containing 1 mg/L of EB in the
following conditions: control (), 10% DMSO (), and phenothiazine
derivatives 1930 (), 2115 () and 2173 () at ½ of their minimum
inhibitory concentration. Accumulation of EB was automatically
monitored on a real-time basis.
Table I. The effect of phenothiazine derivatives on the accumulation of
EB by bacteria.
Compound Enterococcus Salmoella Escherichia Staphylococcus
ID faecalis Enteritidis coli aureus
819 4.02/50 −1.06/50 6.00/50 3.91/25
1821 7.18/50 0.13/50 5.06/50 9.67/50
1930 4.63/50 1.57/12.5 2.62/50 22.83/50
1931 2.64/50 0.05/50 −0.73/50 5.21/50
1932 3.54/50 0.00/50 −1.53/50 −2.89/50
1936 1.25/50 0.22/12.5 3.45/50 15.01/50
1960 0.77/50 0.24/50 −1.57/50 4.59/50
1993 8.81/50 −1.40/50 0.41/50 6.60/50
1994 4.22/50 0.01/50 7.87/50 5.27/50
1995 −0.26/ 5 −0.25/5 −0.30/5 2.95/5
1997 1.73/5 −0.13/5 −0.22/5 2.63/5
1998 0.57/5 −0.05/5 1.08/5 −1.75/5
1999 −2.22/50 −0.58/50 0.77/50 15.13/12.5
2000 −0.15/5 0.23/5 −0.56/5 −3.32/5
2001 3.99/50 −1.14/50 1.45/50 1.60/25
2024 −0.74/50 −1.17/25 0.19/50 6.45/50
2115 4.92/50 −0.41/50 8.13/50 10.70/25
2155 −0.88/50 −0.21/50 −0.03/50 7.37/50
2156 −0.74/50 −0.90/50 1.07/50 1.92/25
2158 51.12/50 8.39/50 42.36/50 28.05/50
2159 −0.59/6.25 −0.31/25 −0.12/50 −1.16/3.2
2160 −0.14/50 −0.15/50 0.19/50 5.51/50
2161 4.75/50 −1.35/12.5 5.35/50 1.41/50
2162 0.89/12.5 0.15/12.5 −0.60 /12.5 −0.95/12.5
2163 −0.63/50 2.10/50 −0.26/50 5.19/50
2164 6.69/25 1.50/50 10.91/50 21.14/50
2165 −1.47/0.8 1.13/12.5 7.21/6.25 2.33/0.8
2166 11.14/50 1.30/50 4.60/50 40.33/50
2167 27.23/25 0.75/50 13.11/50 33.44/50
2168 −1.25/50 −0.44/50 0.22/50 9.10/50
2169 4.17/50 −0.82/25 −1.61/50 5.98/50
2173 0.71/0.8 1.80/50 21.12/25 68.33/12.5
2174 2.42/12.5 0.57/12.5 0.72/12.5 11.31/12.5
2175 −2.28/2.5 −0.09/2.5 0.90/2.5 −1.18/2.5
2176 −1.91/50 −3.85/50 −0.54/50 −2.77/50
2177 −1.04/5 −0.20/5 −0.23/5 −1.35/5
2178 0.81/1.6 0.36/12.5 1.01/12.5 10.38/0.8
2182 −1.24/2.5 0.27/2.5 −0.29/2.5 1.79/2.5
2185 3.97/12.5 0.14/12.5 0.35/12.5 8.76/12.5
2186 0.22/2.5 0.09/2.5 −0.59/2.5 −2.01/2.5
Difference (Δ) in fluorescence compound -Control (no compound)/
concentration at ½ MIC (mg/L). Bacteria were incubated at 37˚C in PBS
(pH 7.4) containing 1 mg/L EB and with and without the phenothiazine
derivative at ½ of its MIC. The difference in the amount of fluorescence
between the compound-containing culture and its control (no compound)
is presented. The variation of amount of fluorescence of controls from
experiment to experiment yielded a standard deviation of ±2.5 relative
fluorescence units. A positive difference of 5 or more fluorescence units
is deemed significant and demonstrates an increase of retained EB due to
an effect on the efflux pump system of the bacterium by the compound.
Compounds deemed effective inhibitors and the resulting amount of
increased relative fluorescence are highlighted in bold.
tetracycline (3), Staphylococcus aureus COLOXA that over-
expresses the NorA efflux pump and is extremely resistant to
oxacillin (6, 18) and two strains of Salmonella Enteritidis that
overexpress the AcrAB efflux pump by 6 times that of their
parental stains and have been induced to high level resistance
to ciprofloxacin (19). Because these efflux pump-mediated
MDR bacteria can be made more sensitive to antibiotics to
which they were resistant by an EPI, such as TZ, that inhibits
their efflux pumps, this phenothiazine was employed as the
positive control. Briefly, none of the compounds at their
highest concentration reduced the MIC of antibiotics for the
Gram-negative bacteria; only compound 2173 reduced the
resistance of the Gram-positive bacteria to oxacillin.
Discussion 
The results of this study show that whereas many of the
compounds have moderate to very potent EPI activity against
the efflux pumps of Gram-positive pathogenic bacteria, fewer
compounds have EPI-like activity against Escherichia coli and
only one, compound 2158, has potent activity against
Salmonella Enteritidis. These results are consistent with the
general response of efflux pumps to EPIs in that the efflux
pumps of Gram-positive bacteria are significantly more
affected by EPI like agents (26). With the exception of
Salmonella Enteritidis, compound 2173 had activity against the
bacteria employed in this study. However, its ability to
significantly reduce efflux-mediated resistance was restricted
to Staphylococcus aureus strains that over-expressed the efflux
pump NorA (COLOXA and HPV 107 strains). Consequently, if
2173 is devoid of any toxicity, it may have some potential for
the therapy of efflux-mediated MDR Staphylococcus strains.
Moreover, because the vast majority of MRSA strains have an
MDR phenotype (27-29), compound 2173 has importance. It
must be mentioned that although many compounds had activity
against the efflux pump of wild type Enterococcus faecalis,
none reduced its resistance to the antibiotic (data not shown);
the inability to reduce resistance lies in the intrinsic basal
resistance of this species to the antibiotic.
Salmonella sp. has many responses to noxious agents that
are invoked subsequent to exposure. Among these is the
activation of genes that regulate and code for the main efflux
pump of the organism, the AcrAB pump (14, 19, 30). As an
example, exposure of Salmonella sp. to concentrations of
chlorpromazine at the MIC or multiples of the MIC, results
in the over-expression of the AcrAB pump (30). However,
when exposed to sub-inhibitory concentrations of
chlorpromazine, the organism at first is susceptible to the
agent for the first four to six hours of exposure, and then
gradually becomes resistant (31). This response to
chlorpromazine has also been observed with exposure of
Salmonella sp. to sub-inhibitory concentrations of TZ (14).
In addition, during the first four to six hours of exposure,
there is a sequential activation of the stress gene soxS,
followed by the global regulator ramA, then by the local
regulator marA, and lastly, acrB (14). These results suggest
that the EPI-like activity of compound 2158 in the EB efflux
assay, an assay that does not support growth since ions
required for growth (K+, Ca2+, etc.) are absent, would soon
be followed in complete medium by the genetic events
associated with progression of Salmonella sp. from a status
of susceptibility to one of extreme resistance (MIC >200
mg/L) to the phenothiazine. Such studies are now on-going. 
In conclusion, the evaluation of forty phenothiazines
derived from a single phenothiazine parent for EPI activity
against pathogenic bacteria whose resistance to given
antibiotics is mediated by over-expression of efflux pumps
suggests that compound 2173, due to its ability to reduce
resistance of MRSA strains to oxacillin, has potential as an
adjunct agent to oxacillin for therapy of MDR infections,
provided that it is relatively toxic-free at concentrations that
are effective. Compound 2158 deserves further study
inasmuch as the compound has significant EPI-like activity
against the efflux pump of Salmonella Enteritidis. 
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